539 related articles for article (PubMed ID: 15821209)
1. Inactive hepatitis B surface antigen carrier state and hepatotoxicity during antituberculosis chemotherapy.
Lee BH; Koh WJ; Choi MS; Suh GY; Chung MP; Kim H; Kwon OJ
Chest; 2005 Apr; 127(4):1304-11. PubMed ID: 15821209
[TBL] [Abstract][Full Text] [Related]
2. [Drug-induced hepatotoxicity caused by anti-tuberculosis drugs in tuberculosis patients complicated with chronic hepatitis].
Kaneko Y; Nagayama N; Kawabe Y; Shimada M; Suzuki J; Kunogi M; Matsui Y; Kawashima M; Suzuki J; Ariga H; Oshima N; Masuda K; Matsui H; Nagai H; Tamura A; Akagawa S; Toyoda E; Machida K; Kurashima A; Yotsumoto H
Kekkaku; 2008 Jan; 83(1):13-9. PubMed ID: 18283910
[TBL] [Abstract][Full Text] [Related]
3. [Secular increase in the incidence rate of drug-induced hepatitis due to anti-tuberculosis chemotherapy including isoniazid and rifampicin].
Nagayama N; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H; Mohri M
Kekkaku; 2003 Apr; 78(4):339-46. PubMed ID: 12739393
[TBL] [Abstract][Full Text] [Related]
4. A prospective clinical study of isoniazid-rifampicin-pyrazinamide-induced liver injury in an area endemic for hepatitis B.
Hwang SJ; Wu JC; Lee CN; Yen FS; Lu CL; Lin TP; Lee SD
J Gastroenterol Hepatol; 1997 Jan; 12(1):87-91. PubMed ID: 9076631
[TBL] [Abstract][Full Text] [Related]
5. Hepatitis C virus infection and hepatotoxicity during antituberculosis chemotherapy.
Kwon YS; Koh WJ; Suh GY; Chung MP; Kim H; Kwon OJ
Chest; 2007 Mar; 131(3):803-808. PubMed ID: 17356096
[TBL] [Abstract][Full Text] [Related]
6. Hepatotoxicity of pyrazinamide: cohort and case-control analyses.
Chang KC; Leung CC; Yew WW; Lau TY; Tam CM
Am J Respir Crit Care Med; 2008 Jun; 177(12):1391-6. PubMed ID: 18388355
[TBL] [Abstract][Full Text] [Related]
7. Risk factors for antituberculous chemotherapy-induced hepatotoxicity in Japanese pediatric patients.
Ohkawa K; Hashiguchi M; Ohno K; Kiuchi C; Takahashi S; Kondo S; Echizen H; Ogata H
Clin Pharmacol Ther; 2002 Aug; 72(2):220-6. PubMed ID: 12189369
[TBL] [Abstract][Full Text] [Related]
8. [Effectiveness and problems of PZA-containing 6-month regimen for the treatment of new pulmonary tuberculosis patients].
Wada M
Kekkaku; 2001 Jan; 76(1):33-43. PubMed ID: 11211781
[TBL] [Abstract][Full Text] [Related]
9. Liver injury during antituberculosis treatment: an 11-year study.
Døssing M; Wilcke JT; Askgaard DS; Nybo B
Tuber Lung Dis; 1996 Aug; 77(4):335-40. PubMed ID: 8796249
[TBL] [Abstract][Full Text] [Related]
10. Protective effect of N-acetylcysteine on antituberculosis drug-induced hepatotoxicity.
Baniasadi S; Eftekhari P; Tabarsi P; Fahimi F; Raoufy MR; Masjedi MR; Velayati AA
Eur J Gastroenterol Hepatol; 2010 Oct; 22(10):1235-8. PubMed ID: 20461008
[TBL] [Abstract][Full Text] [Related]
11. Hepatotoxicity During Isoniazid Preventive Therapy and Antiretroviral Therapy in People Living With HIV With Severe Immunosuppression: A Secondary Analysis of a Multi-Country Open-Label Randomized Controlled Clinical Trial.
Ngongondo M; Miyahara S; Hughes MD; Sun X; Bisson GP; Gupta A; Kumwenda J; Lavenberg JA; Torres TS; Nyirenda M; Kidonge KK; Hosseinipour MC;
J Acquir Immune Defic Syndr; 2018 May; 78(1):54-61. PubMed ID: 29406428
[TBL] [Abstract][Full Text] [Related]
12. Antituberculosis drug-induced hepatotoxicity: concise up-to-date review.
Tostmann A; Boeree MJ; Aarnoutse RE; de Lange WC; van der Ven AJ; Dekhuijzen R
J Gastroenterol Hepatol; 2008 Feb; 23(2):192-202. PubMed ID: 17995946
[TBL] [Abstract][Full Text] [Related]
13. Drug-induced hepatotoxicity of anti-tuberculosis drugs and their serum levels.
Jeong I; Park JS; Cho YJ; Yoon HI; Song J; Lee CT; Lee JH
J Korean Med Sci; 2015 Feb; 30(2):167-72. PubMed ID: 25653488
[TBL] [Abstract][Full Text] [Related]
14. [Can HBsAg levels guide to differentiate inactive HBsAg carriers from HBeAg negative chronic B hepatitis?].
Sayan M; Mutlu B; Erdoğan S; Meriç M; Willke A
Mikrobiyol Bul; 2007 Jan; 41(1):87-93. PubMed ID: 17427556
[TBL] [Abstract][Full Text] [Related]
15. Pyrazinamide and rifampin vs isoniazid for the treatment of latent tuberculosis: improved completion rates but more hepatotoxicity.
McNeill L; Allen M; Estrada C; Cook P
Chest; 2003 Jan; 123(1):102-6. PubMed ID: 12527609
[TBL] [Abstract][Full Text] [Related]
16. Risk factors for side-effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis.
Schaberg T; Rebhan K; Lode H
Eur Respir J; 1996 Oct; 9(10):2026-30. PubMed ID: 8902462
[TBL] [Abstract][Full Text] [Related]
17. Prevalence and interaction of hepatitis B and latent tuberculosis in Vietnamese immigrants to the United States.
Patel PA; Voigt MD
Am J Gastroenterol; 2002 May; 97(5):1198-203. PubMed ID: 12014728
[TBL] [Abstract][Full Text] [Related]
18. Hepatotoxicity of antituberculosis therapy (rifampicin, isoniazid and pyrazinamide) or viral hepatitis.
Türktaş H; Unsal M; Tülek N; Orüç O
Tuber Lung Dis; 1994 Feb; 75(1):58-60. PubMed ID: 8161767
[TBL] [Abstract][Full Text] [Related]
19. Antituberculosis drug-induced hepatotoxicity: a comparison between patients with and without human immunodeficiency virus seropositivity.
Coca NS; Oliveira MS; Voieta I; Antunes CM; Lambertucci JR
Rev Soc Bras Med Trop; 2010; 43(6):624-8. PubMed ID: 21181011
[TBL] [Abstract][Full Text] [Related]
20. Risk factors for hepatotoxicity induced by antituberculosis drugs.
Devoto FM; González C; Iannantuono R; Serra HA; González CD; Sáenz C
Acta Physiol Pharmacol Ther Latinoam; 1997; 47(4):197-202. PubMed ID: 9504179
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
